

**BioVendor
Group**

NGS

BIOVENDOR.GROUP

ENG

fastGEN

**A breakthrough system
for a one-step NGS
library preparation**

**GTTCAATATTGCGATGT
CCGATGGTACAGGCAC
GATGCTACAGGCCAGC**

**0100001 1010101 100110
0001001 1011010 1110101**

Meet the fastGEN technology

Introducing our cutting-edge sequencing solution fastGEN, built on the advanced NGS technology for unparalleled efficiency and user-friendliness.

With an easy-to-use software and diagnostic panels tailored for DNA and RNA analysis, coupled with prompt service and expertise from our application specialists, we are driving a revolution in laboratory diagnostics speed and the availability of personalized medicine.

BioVendor Group developed user-friendly diagnostic NGS kits with excellent analytical parameters and high-speed processing.

Meet our NGS technology team



Iveta Tóthová, Ph.D.

Senior Operational Product Manager
tothova@biovendor-mdx.com



Anna Kolouchová, Ph.D.

Area Sales Manager
kolouchova@biovendor-mdx.com



MSc. Adam Novotný

Application Specialist
novotny@biovendor-mdx.com



Mgr. Tereza Hubinková

Operational Product Manager
hubinkova@biovendor-mdx.com



Mgr. Petr Fajkus, Ph.D.

Application Specialist GENOVESA
fajkus@biovendor-mdx.com

It's faster. Way faster!

Quick & easy detection of mutations in oncomarkers

The fastGEN technology is based on a rapid and easy-handling workflow what significantly lowers the probability of mistakes. The principle of fastGEN is ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with specially labeled hybrid primers. FastGEN technology strategically focuses on codons with established treatment options, marking a revolutionary advancement in personalised medicine.

Unique

Simple, ultra-sensitive, specific,
and effective technology

Fast

Excellent speed
(<30 min hands-on time)

Reliable

Significantly lower probability of mistakes,
uniform coverage for different amplicons
and different samples

Robust

Robustness achieved by using short
amplicons obtained by a single polymerase
chain reaction with special tagged
hybrid primers

Type of samples suitable for fastGEN technology



DNA isolated from tumor tissue




DNA isolated from FFPE tissue samples



Circulating tumor DNA isolated from blood


State-of-the-art prototyping workflow

1.




Samples and Master Mixes with different indexes are mixed (10 min).

2.




Reactions are set up using a Real-Time PCR device.

3.




Indexed amplicons are pooled (5 min).

4.




DNA is purified (10 min).

5.



DNA is diluted and denatured (10 min).

6.



DNA is sequenced using an Illumina sequencer.

7.



Raw data are analysed with GENOVESA software.




Total time: 4 hours | Hands-on-time: 30 minutes

GENOVESA

Cloud-based database bioinformatic
and interpretation system

Key features

- Comprehensive variant detection workflows (CNV, MSI, TMB, HRD)
- Automated bioinformatics pipelines from FASTQ to clinical report
- Advanced QC metrics
- Integrated somatic and germline workflows for oncology and inherited disease panels
- Customizable analysis settings for amplicons, panels, CES, WES, WGS
- Built-in annotation databases (clinical, population, oncological)
- Easy variant filtration and prioritization
- Local clinical variants database with internal knowledge accumulation



From FASTQ to clinical report

GENOVESA enables comprehensive evaluation of NGS data across a wide range of applications - from ampliconbased assays and targeted panels to clinical exome (CES), whole exome (WES), and whole genome sequencing (WGS). The platform supports both DNA and RNA sequencing inputs and performs automated quality control of FASTQ, BAM, and VCF files. Integrated annotation databases, customizable workflows, and in-platform variant interpretation allow efficient data analysis and clinical decision support. GENOVESA further supports complete clinical case management with integration of International Classification of Diseases and HPO terminology.

Sequencing technology

GENOVESA supports analysis of conventional sequencing data (FASTQ, BAM, VCF) regardless of what sequencing technology was used – Illumina, MGI, PacBio, Oxford Nanopore Technologies, Genapsys and many others.

Databases and data sharing

GENOVESA also serves as a database for storing variants, with the possibility of sharing data between individual clinics.

Security

GENOVESA prioritizes data security through HTTPS encryption. We do not rely on third-party providers like Google or Amazon; instead, we host your data in our secure data center located in Prague. We do not collect any sensitive patient data, GENOVESA is fully GDPR compliant.

Find out more about
the software on our
[website.](#)



fastGEN BCR::ABL1 Cancer kit for hemato-oncology

Molecular monitoring of patients with chronic myeloid leukemia (CML) is a key part of the treatment protocol during the use of tyrosine kinase inhibitors (TKIs). The BCR::ABL1 fusion gene produces the pathological, constitutively activated tyrosine kinase Bcr-Abl, which is responsible for the uncontrolled proliferation of hematopoietic cells and their reduced response to proapoptotic signals.

The fastGEN technology provides a method of sensitive, specific and time-efficient examination of the mutational status of *BCR::ABL1* using NGS technology.

**The kit covers
codons 237-510**

**Major, minor and
micro break-point**

**Extraordinary
sensitivity**

**Monitoring the level of minimal
residual disease (MRD)**

fastGEN

BCR::ABL1

AGATGGTACAGGCC
GTTCAATATTGCGA
CCGATGGTACAGGC
GATGCTACAGGCCA
1000011010101100
0010011011010111
1000100101011010
11100101100001101
00010011011010111

Single technology, multiple opportunities

Kit and data analysis in one package

Kits

Cat. No.	Product	Gene	Detail	Status
RDNGS0001	fastGEN SOLID Cancer Kit	<i>NRAS, KRAS, BRAF</i>	<i>NRAS, KRAS</i> : codons 12, 13, 59, 60, 61, 117 and 146; <i>BRAF</i> : codons 600	CE IVD
RDNGS0002	fastGEN LUNG Cancer Kit	<i>EGFR</i>	exons 18, 19, 20 and 21	CE IVD
RDNGS0003	fastGEN BRAIN Cancer Kit	<i>IDH1, IDH2</i>	<i>IDH1</i> : codon 132 <i>IDH2</i> : codons 140 and 172	CE IVD
RDNGS0007	fastGEN PIK3CA Cancer Kit	<i>PIK3CA</i>	exons 2, 3, 5, 7, 8, 10, 14 and 21	RUO
RDNGS0008	fastGEN TERT Cancer Kit	<i>TERT</i>	promotor and mutations C228T a C250T	RUO
RDNGS0009 RDNGS0009-32	fastGEN TP53 Cancer Kit	<i>TP53</i>	exons 2-11, 2 non-canonical exons (between exon 9 and 10) and adjacent introns (min 6 nt)	RUO
RDNGS0010	fastGEN POLE/ CTNNB1 Cancer Kit	<i>POLE, CTNNB1</i>	<i>POLE</i> : exons 9, 11, 13 and 14 <i>CTNNB1</i> : exons 3, 7 and 8	RUO
RDNGS0011	fastGEN BCR::ABL1 Cancer Kit	<i>ABL1, BCR</i>	<i>BCR::ABL1</i> : minor and major breakpoint	RUO
RDNGS0016	fastGEN H3F3A/IDH1/2 Cancer Kit	<i>H3F3A, IDH1, IDH2</i>	<i>IDH1</i> - codon 132 <i>IDH2</i> - codons 140 and 172 <i>H3F3A</i> - codons 28 and 35	RUO
RDNGS0018	fastGEN Food Intolerance Kit	<i>ALDOB, AOCT1, MCM6</i>	<i>ALDOB1</i> : rs118204429, rs387906225, rs1800546, rs76917243, rs78340951, rs77718928, rs370793608, rs764826805 <i>AOC1</i> : rs10156191, rs1049742, rs2268999, rs1049793, rs2052129 <i>MCM6</i> : rs4988235, rs182549	RUO
RDNGS0019	fastGEN MSI Kit	12 genes	Microsatellite stability	RUO
RDNGS0020-32	fastGEN EGFR/HER2 Cancer Kit	<i>EGFR, HER2</i>	<i>EGFR</i> : exons 18, 19, 20 and 21 <i>HER2</i> : exons 7, 8, 17, 19, 20 and 21	RUO
RDNGS0021	fastGEN MPN Cancer Kit	<i>CALR, JAK2, MPL</i>	<i>CALR</i> : exon 9 <i>JAK2</i> : 12, 13, 14, 16 <i>MPL</i> : 4, 10, 12	RUO
RDNGS1001	fastGEN SOLID II Cancer Kit	<i>NRAS, KRAS, BRAF</i>	<i>NRAS, KRAS</i> : codons 12, 13, 59, 60, 61, 117 and 146; <i>BRAF</i> : codons 600 and 601	RUO

CE The kits are CE-IVD certified
IVD and intended for professional use.

Kit components

The kit contains ready-to-use Master Mixes with 16 sample indexes, read1, read2 seq primers and an index seq primer.





FOLLOW US

BIOVENDOR.GROUP



GTTCAATATTGCGATGTT
CCGATGGTACAGGCACA
GATGCTACAGGCCAGCT

0100001 1010101 10011010
0001001 1011010 11101010

Contacts

Iveta Tóthová, PhD.
Senior Operational Product Manager
tothova@biovendor-mdx.com

Anna Kolouchová, Ph.D.
Area Sales Manager
kolouchova@biovendor-mdx.com

MSc. Adam Novotný
Application Specialist
novotny@biovendor-mdx.com

Mgr. Tereza Hubinková
Operational Product Manager
hubinkova@biovendor-mdx.com

Mgr. Petr Fajkus, Ph.D.
Application Specialist GENOVESA
fajkus@biovendor-mdx.com

BioVendor – Laboratorní medicína s.r.o.

Karásek 1767/1, 621 00 Brno
Czech Republic
info@biovendor-mdx.com
www.biovendor.com